Sanofi Aims to Add Second-Generation Lemtrada to Pipeline

Sanofi plans to develop a new version of the experimental therapy Lemtrada as the French drugmaker seeks to expand the multiple sclerosis business it’s built since the purchase of Genzyme Corp.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.